DROSPIRENONE

PRODUCT IDENTIFICATION
CAS NO. 67392-87-4

DROSPIRENONE

EINECS NO. 266-679-2
FORMULA C24H30O3
MOL WT. 366.49

H.S. CODE

  

TOXICITY

  
SYNONYMS 1,2-Dihydrospirorenone;
6-beta,7-beta;15-beta,16-beta-Dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone; (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16- Hexadeca hydro-10,13-dimethylspiro-(17H-dicyclopropa(6,7:15,16)cyclopenta(a) phenanthrene-17, 2'(5'H)-furan)-3,5'(2H)-dione;  Dehydrospirorenone;
DERIVATION

 

CLASSIFICATION

  

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

white to off-white crystalline powder

MELTING POINT 196 - 200 C
BOILING POINT

 

SPECIFIC GRAVITY  
SOLUBILITY IN WATER  
pH  
VAPOR DENSITY

 

REFRACTIVE INDEX

 

NFPA RATINGS

  

AUTOIGNITION

 

FLASH POINT

 

STABILITY Stable under normal conditions.

GENERAL DESCRIPTION & APPLICATIONS

Spironolactone is a is a synthetic 17-lactone steroid belong to a class of drugs called potassium-sparing diuretics which inhibit the exchange of sodium for potassium and hydrogen ions in the distal tubule. It acts as a competitive aldosterone antagonist in the distal renal tubules. Anti-androgen effect is also utilized as a component of hormone replacement therapy for transgender, in the treatment of hair loss, female hirsutism and acne but it can lead to adverse effects. Spironolactone, as a potassium-sparing diuretic, increases the secretion of water and sodium, while decreasing the excretion of potassium. Aldosterone synthesis is stimulated by increased plasma angiotensin II or potassium levels, which are present in proportion to plasma sodium deficiencies. Spironolactone is mainly used in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hypokalemia. Spironolactone itself is a weak diuretic, and it is used in combination with other diuretics. Angiotensin II antagonist such as valsartan, eprosartan and telmisartan decrease the effects of aldosterone and used as antihypertensive. Drospirenone is a spironolactone analogue with antagonism of aldosterone. It is used in combination with an estrogen component as an oral contraceptive. Members of aldosterone antagonists include;

Aldosterone Antagonist

CAS RN
17alpha-Hydroxy-6beta,7beta-methylene-3-oxo-D-homo-17aalpha-pregna-4,16- dien-21- carboxylic acid 81844-75-9
17beta-Hydroxy-12-alpha-etiojerv-4-en-3-one 22785-18-8
17-Hydroxy-3-oxo-17 alpha-pregn-4-ene-7 alpha,21-dicarboxylic acid 7-methylester gamma-lactone 41020-65-9
17-Hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic acid, 7-(1-methylethyl) ester potassium 41020-87-5
17-Hydroxy-3-oxo-19-nor-17alpha-pregn-4-ene-21-carboxylic acid gamma-lactone 1722-54-9
18-Deoxyaldosterone 2507-88-2
3,20-Dioxopregn-4-ene-18'-carboxaldehyde cyclic 18'-(1,2-ethandiylmercaptal) 123376-04-5
5-Oxo-A-tetranor-17-alpha-pregna-9,11-diene-21-17-carbolactone 76225-44-0
6,7-Epoxycanrenone 114577-01-4
7alpha-(Methylthio)spironolactone S-oxide 38753-75-2
7alpha-Thiospironolactone 38753-76-3
7-Thiomethylspirolactone 38753-77-4
Aldatense 76270-05-8
Canrenoate Potassium 2181-04-6
Canrenone 976-71-6
Dicirenone 41020-79-5
Dihydroxy-6,7-dihydrocanrenone 67483-35-6
Drospirenone 67392-87-4
Eplerenone 107724-20-9
Mespirenone 87952-98-5
Mexrenoate potassium anhydrous 41020-67-1
Mexrenoate potassium 43169-54-6
Oxprenoate potassium 76676-34-1
Prorenoate 49848-01-3
Prorenoate potassium 49847-97-4
Prorenone 49848-04-6
Spironolactone 52-01-7
Spirorenone 74220-07-8
SALES SPECIFICATION

APPEARANCE

white to off-white crystalline powder
IDENTIFICATION

pass Test A (IR)

ASSAY

99.0% min

LOSS ON DRYING

0.5% max

RESIDUE ON IGNITION

0.2% max

HEAVY METALS

10ppm max

MELTING POINT

160 - 166 C

OPTICAL ROTATION

-183° ~ -179°
TRANSPORTATION
PACKING
 
HAZARD CLASS  
UN NO.  
OTHER INFORMATION